All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Once-weekly dosing of carfilzomib approved by FDA
Bookmark this article
The US Food and Drug Administration (FDA) has approved a once-weekly dosing regimen of carfilzomib (Kyprolis®) in combination with dexamethasone, to treat patients with relapsed and refractory multiple myeloma (MM). The new indication enables a single 70 mg/m2 dose to be administered once-weekly (along with dexamethasone), instead of the previous twice-weekly dose of 27 mg/m2.
The approval was based on the ARROW study presented at ASCO in June 2018, and previously detailed in an interview for the MM Hub by Maria Victoria Mateos. The study showed an improved PFS in patients receiving the once-weekly regimen and in addition, offers a more convenient regimen.
Your opinion matters
59 votes - 53 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox